---
title: "HEARTSCIENCES INC C/WTS (TO PUR COM) | 10-K: FY2025 Revenue: USD 4 K"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/250020860.md"
datetime: "2025-07-24T20:06:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/250020860.md)
  - [en](https://longbridge.com/en/news/250020860.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/250020860.md)
---

# HEARTSCIENCES INC C/WTS (TO PUR COM) | 10-K: FY2025 Revenue: USD 4 K

Revenue: As of FY2025, the actual value is USD 4 K.

EPS: As of FY2025, the actual value is USD -9.34.

EBIT: As of FY2025, the actual value is USD -8.353 M.

### Segment Revenue

-   Revenue for the year ended April 30, 2025 was $4,000, compared to $19,000 for the year ended April 30, 2024, representing a decrease of 79%.

### Operational Metrics

-   **Net Loss**: The net loss for the year ended April 30, 2025 was $8.8 million, compared to $6.6 million for the year ended April 30, 2024, representing an increase of 33%.
-   **Gross Margin**: Gross margin for the year ended April 30, 2025 was $2,000, compared to $13,000 for the year ended April 30, 2024, representing a decrease of 85%.
-   **Research and Development Expenses**: R&D expenses for the year ended April 30, 2025 were $4.4 million, compared to $2.9 million for the year ended April 30, 2024, representing an increase of 52%.
-   **Selling, General and Administrative Expenses**: Selling, general, and administrative expenses for the year ended April 30, 2025 were $3.9 million, compared to $3.4 million for the year ended April 30, 2024, representing an increase of 15%.

### Cash Flow

-   **Operating Cash Flow**: Net cash used in operating activities for the year ended April 30, 2025 was $7.4 million, compared to $6.1 million for the year ended April 30, 2024.
-   **Free Cash Flow**: Net cash used in investing activities for the year ended April 30, 2025 was $30,000, compared to $125,000 for the year ended April 30, 2024.

### Unique Metrics

-   **Debt Financing**: The Company issued an unsecured note in the original principal amount of $2,510,000 to Streeterville Capital, LLC, with net proceeds of approximately $1.9 million after original issue discount and transaction expenses.

### Outlook / Guidance

-   The Company plans to continue devoting significant capital resources to R&D, clinical studies, and go-to-market strategies. Additional funding will be required to support the sales launch of its products into the U.S., provide working capital, and support further R&D.

### Related Stocks

- [HSCSW.US](https://longbridge.com/en/quote/HSCSW.US.md)

## Related News & Research

- [Prediction: Vanguard's S&P 500 ETF Will Be Back Above $1 Trillion in Assets Before the Year Is Out. Here's the Math.](https://longbridge.com/en/news/294609950.md)
- [ROI-OPEC+ oil output hike is irrelevant for now, not for later: Russell](https://longbridge.com/en/news/294620367.md)
- [ANALYSIS-Obesity battle heats up again as Novo claws way back into race with Lilly](https://longbridge.com/en/news/294641770.md)
- [Can Caterpillar (CAT) Justify Its Valuation As AI Data Center Optimism Meets Earnings?](https://longbridge.com/en/news/294635551.md)
- [Lattice Semiconductor Earnings: What To Look For From LSCC](https://longbridge.com/en/news/294635740.md)